secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066366
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q1 net loss $11.0M; cash $65.5M, runs into 2H'26; first patient dosed in Phase 2a Part B for AA
--------------------------------------------------------------------------------

- Net loss $(11.0)M ($(0.90)/share) vs. net income $1.0M in Q1 2024; R&D expense $7.1M (down 28% YoY).
- Cash and equivalents $65.5M as of March 31, 2025; expected to fund operations into 2H'26.
- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data expected 1H'26.
- Fast Track designation granted to bempikibart for alopecia areata; durable responses seen in late-breaking AAD presentation.
- First patient dosed in Part A open-label extension; median follow-up 41 weeks shows maintenance or further hair growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025066366/0000950170-25-066366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025066366/qttb-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer